Lei Chu, MD
Urology · Houston, TXNPI 1831354851
Payments from drug & device makers
Across 216 payments — averaging $44.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Neotract Inc.$852
- Antares Pharma, Inc.$634
- Astellas Pharma US Inc$535
- Medtronic$505
- Sumitomo Pharma America, Inc.$471
- plus $2K from 27 others
What the payments were for
- Travel & lodging$5856%
- Food & beverage$3,70638%
- Education$4,98352%
- Gifts$3634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $4,500 |
| Neotract Inc. | 3 | $852 |
| Antares Pharma, Inc. | 36 | $634 |
| Astellas Pharma US Inc | 12 | $535 |
| Medtronic(2 entities) | 18 | $505 |
| Sumitomo Pharma America, Inc. | 43 | $471 |
| Olympus America Inc. | 3 | $400 |
| Urovant Sciences Inc | 36 | $381 |
| Axonics, Inc. | 14 | $307 |
| Boston Scientific | 8 | $239 |
| Pfizer | 8 | $146 |
| Halozyme Inc | 3 | $59 |
| Urogen Pharma, Inc. | 3 | $59 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $41 |
| Caldera Medical, Inc | 1 | $41 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $37 |
| Laborie Medical Technologies Corp. | 1 | $35 |
| Acerus Pharmaceuticals Corporation | 2 | $32 |
| Coloplast | 2 | $30 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Procept Biorobotics Corporation | 1 | $28 |
| Amniox Medical, Inc. | 1 | $27 |
| Telix Pharmaceuticals | 1 | $26 |
| Mission Pharmacal Company | 2 | $26 |
| Johnson & Johnson | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Convatec Inc. | 1 | $12 |
| Abbott | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$4,500
- UroLift$852
- Olympus Cystoscopes$363
- INTERSTIM$142
How this compares
$9,637 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 204 | $188,177 |
| Lupron DepotLeuprolide Acetate | 26 | $153,728 |
| MyrbetriqMirabegron | 185 | $146,369 |
| OrgovyxRelugolix | 18 | $49,020 |
| Estradiol | 284 | $14,665 |
| Trospium Chloride | 322 | $13,156 |
| Tamsulosin Hcl | 614 | $6,579 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 420 | $6,019 |
| Mirabegron ErMirabegron | 14 | $5,279 |
| Methenamine Hippurate | 23 | $3,826 |
| Testosterone Cypionate | 68 | $3,741 |
| CefuroximeCefuroxime Axetil | 115 | $3,233 |
| Silodosin | 29 | $2,995 |
| Finasteride | 329 | $2,920 |
| NitrofurantoinNitrofurantoin Macrocrystal | 79 | $2,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $471 | $237,197222 claims |
| Astellas Pharma US IncMyrbetriq | $535 | $146,369185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 urology providers in Texas.
Other urology in Houston
- Zvi SchiffmanHouston$17.8M
- Jose KaramHouston$5.7M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Brian ChapinHouston$1.1M
- Arun RaiHouston$1M
- Ashish KamatHouston$957K
- Donald GriffithHouston$732K
- Robert CornellHouston$695K
- John DavisHouston$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.